Oncorus Inc. (ONCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCR Stock Price Chart Interactive Chart >
ONCR Price/Volume Stats
| Current price | $0.46 | 52-week high | $6.08 |
| Prev. close | $0.45 | 52-week low | $0.41 |
| Day low | $0.45 | Volume | 69,000 |
| Day high | $0.50 | Avg. volume | 131,731 |
| 50-day MA | $0.69 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 11.93M |
Oncorus Inc. (ONCR) Company Bio
Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.
Latest ONCR News From Around the Web
Below are the latest news stories about ONCORUS INC that investors may wish to consider to help them evaluate ONCR as an investment opportunity.
Oncorus to Participate in Upcoming Investor ConferencesANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences: Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.Piper Sandler 34th Annual Healthcare Conference |
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual MeetingONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 expresses four immunomodulatory payloads, including IL-12, an anti-PD-1 nanobody, 15-hydroxyprostaglandin dehydrogenase (HPGD), and a novel macrophage-modulating Fc-enhanced antibody to reverse GBM’s immunosu |
Oncorus (ONCR) Gets a Buy from H.C. WainwrightIn a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Oncorus (ONCR - Research Report), with a price target of $7.00. The company's shares closed last Friday at $0.57.According to TipRanks, Ramakanth is an analyst with an average return of -13.5% and a 28.60% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, MiMedx Group, and Rewalk Robotics.Currently, the analyst consensus on Oncorus is a Moderate Buy with an average price target of $6.50, implying a 1,033.39% upside from current levels. In a report released on November 2, Piper Sandler also maintained a Buy rating on the stock with a $6. |
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the UpgradeOncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Recap: Oncorus Q3 EarningsOncorus (NASDAQ: ONCR ) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Oncorus missed estimated earnings by 1.33%, reporting an EPS of $-0.76 versus … Full story available on Benzinga.com |
ONCR Price Returns
| 1-mo | -19.79% |
| 3-mo | N/A |
| 6-mo | -72.12% |
| 1-year | -91.86% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -91.27% |
| 2021 | -83.70% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...